BioArctic's partner Eisai launches Leqembi in South Korea to treat MCI due to AD or mild AD dementia
BioArctic AB’s (publ) partner Eisai announced that Leqembi (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer’s …